"Kaplan-Meier Estimate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
    
			
			
				
				
					
						| Descriptor ID | D053208 | 
					
						| MeSH Number(s) | E05.318.740.998.650 N05.715.360.750.795.650 N06.850.520.830.998.650 | 
					
						| Concept/Terms | Kaplan-Meier EstimateKaplan-Meier EstimateEstimate, Kaplan-MeierKaplan-Meier TestKaplan Meier TestTest, Kaplan-MeierProduct-Limit MethodMethod, Product-LimitMethods, Product-LimitProduct Limit MethodProduct-Limit MethodsKaplan-Meier AnalysisAnalysis, Kaplan-MeierKaplan Meier Analysis
 Kaplan-Meier Survival CurvesKaplan-Meier Survival CurvesCurves, Kaplan-Meier SurvivalKaplan Meier Survival CurvesSurvival Curves, Kaplan-Meier
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Kaplan-Meier Estimate".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Kaplan-Meier Estimate".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Kaplan-Meier Estimate" by people in this website by year, and whether "Kaplan-Meier Estimate" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2006 | 0 | 3 | 3 | 
| 2007 | 0 | 13 | 13 | 
| 2008 | 0 | 16 | 16 | 
| 2009 | 0 | 41 | 41 | 
| 2010 | 0 | 32 | 32 | 
| 2011 | 0 | 50 | 50 | 
| 2012 | 0 | 59 | 59 | 
| 2013 | 1 | 41 | 42 | 
| 2014 | 1 | 51 | 52 | 
| 2015 | 0 | 51 | 51 | 
| 2016 | 0 | 41 | 41 | 
| 2017 | 0 | 63 | 63 | 
| 2018 | 0 | 39 | 39 | 
| 2019 | 0 | 37 | 37 | 
| 2020 | 0 | 28 | 28 | 
| 2021 | 0 | 9 | 9 | 
| 2022 | 0 | 5 | 5 | 
| 2023 | 0 | 1 | 1 | 
| 2024 | 1 | 11 | 12 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Kaplan-Meier Estimate" by people in Profiles.
						
					
								- 
								Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891. 
- 
								Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665. 
- 
								Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 02; 392(1):45-55. 
- 
								Radiomics analysis of cerebral blood flow suggests a possible link between perfusion homogeneity and poor glioblastoma multiforme prognosis. Biomed Phys Eng Express. 2024 09 09; 10(6). 
- 
								Invasive Treatment Strategy for Older Patients with Myocardial Infarction. N Engl J Med. 2024 11 07; 391(18):1673-1684. 
- 
								Impact of proton versus photon adjuvant radiotherapy on overall survival in the management of skull base and spinal chordomas: a National Cancer Database analysis. J Neurosurg. 2025 Jan 01; 142(1):239-247. 
- 
								Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 08 22; 391(8):710-721. 
- 
								Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25; 391(4):320-333. 
- 
								Optimizing pediatric liver transplantation: Evaluating the impact of donor age and graft type on patient survival outcome. Pediatr Transplant. 2024 Jun; 28(4):e14771. 
- 
								Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.